Free Trial

Johnson & Johnson (JNJ) Stock Forecast & Price Target

Johnson & Johnson logo
$190.97 +1.28 (+0.67%)
Closing price 03:59 PM Eastern
Extended Trading
$191.75 +0.78 (+0.41%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Johnson & Johnson - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
0
Hold
8
Buy
14

Based on 22 Wall Street analysts who have issued ratings for Johnson & Johnson in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 22 analysts, 8 have given a hold rating, 12 have given a buy rating, and 2 have given a strong buy rating for JNJ.

Consensus Price Target

$191.41
0.23% Upside
According to the 22 analysts' twelve-month price targets for Johnson & Johnson, the average price target is $191.41. The highest price target for JNJ is $215.00, while the lowest price target for JNJ is $153.00. The average price target represents a forecasted upside of 0.23% from the current price of $190.97.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for JNJ and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Johnson & Johnson and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

JNJ Analyst Ratings Over Time

TypeCurrent Forecast
10/9/24 to 10/9/25
1 Month Ago
9/9/24 to 9/9/25
3 Months Ago
7/11/24 to 7/11/25
1 Year Ago
10/10/23 to 10/9/24
Strong Buy
2 Strong Buy rating(s)
2 Strong Buy rating(s)
2 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
12 Buy rating(s)
9 Buy rating(s)
7 Buy rating(s)
6 Buy rating(s)
Hold
8 Hold rating(s)
9 Hold rating(s)
11 Hold rating(s)
7 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$191.41$176.29$171.00$173.43
Forecasted Upside0.23% Upside-0.47% Downside9.01% Upside7.93% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyHold

JNJ Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

JNJ Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Johnson & Johnson Stock vs. The Competition

TypeJohnson & JohnsonMedical CompaniesS&P 500
Consensus Rating Score
2.73
2.33
2.52
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside0.45% Upside1,064.12% Upside173.09% Upside
News Sentiment Rating
Positive News

See Recent JNJ News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
10/9/2025The Goldman Sachs Group
3 of 5 stars
Asad Haider
Not Rated
Boost TargetBuy$186.00 ➝ $212.00+11.19%
10/8/2025Weiss Ratings
0 of 5 stars
 UpgradeHold (C+)Buy (B-)
10/7/2025Citigroup
3 of 5 stars
Joanne Wuensch
Joanne Wuensch
4 of 5 stars
Boost TargetBuy$200.00 ➝ $213.00+14.80%
10/6/2025Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetMarket Perform$172.00 ➝ $193.00+2.38%
10/3/2025UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Target$198.00+6.46%
10/3/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set TargetEqual WeightOverweight$170.00 ➝ $212.00+13.99%
10/3/2025Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetNeutral$175.00 ➝ $198.00+5.47%
9/30/2025HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost Target$188.00 ➝ $210.00+11.40%
9/23/2025Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeNeutralBuy$167.00 ➝ $206.00+18.24%
9/16/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetNeutral$185.00 ➝ $200.00+13.33%
7/23/2025Erste Group Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 UpgradeHoldBuy
7/17/2025Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingOverweight
7/17/2025Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetEqual Weight$165.00 ➝ $176.00+8.13%
7/17/2025Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOutperform$181.00 ➝ $185.00+13.50%
7/17/2025Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetEqual Weight$171.00 ➝ $176.00+6.81%
5/13/2025Leerink Partnrs
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
5/13/2025Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOutperformMarket Perform$169.00 ➝ $153.00-0.57%
4/24/2025Benchmark
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
4/14/2025Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetOutperform$165.00 ➝ $162.00+5.42%
1/24/2025Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
1/23/2025Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetHold$170.00 ➝ $155.00+5.58%
11/15/2024Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$190.00+25.12%
10/16/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingOverweight$215.00 ➝ $215.00+30.70%
7/23/2024Daiwa America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
7/23/2024Daiwa Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 DowngradeOutperformNeutral$160.00 ➝ $150.00-2.75%
7/18/2024TD Securities
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower Target$195.00 ➝ $185.00+18.03%
7/18/2024TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetBuy$195.00 ➝ $185.00+18.38%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 12:00 AM ET.


Should I Buy Johnson & Johnson Stock? JNJ Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, October 6, 2025. Please send any questions or comments about these Johnson & Johnson pros and cons to contact@marketbeat.com.

Johnson & Johnson
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Johnson & Johnson:

  • The current stock price is around $177, reflecting a strong position in the market and potential for growth.
  • Johnson & Johnson has a solid dividend payout ratio of approximately 55.61%, indicating a commitment to returning value to shareholders through regular dividends.
  • Recent earnings reports show that the company exceeded analysts' expectations, with earnings per share (EPS) of $2.77, which is a positive indicator of financial health and operational efficiency.
  • Analysts have set a consensus target price of about $188.88, suggesting that there is room for price appreciation, making it an attractive investment opportunity.
  • The company has a strong return on equity of 32.49%, which demonstrates effective management and profitability, appealing to investors looking for robust financial performance.

Johnson & Johnson
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Johnson & Johnson for these reasons:

  • Despite recent positive earnings, the company reported a slight decrease in EPS compared to the previous year, which may raise concerns about future growth potential.
  • Johnson & Johnson's quick ratio is 0.76, indicating potential liquidity issues, as it suggests the company may not have enough short-term assets to cover its short-term liabilities.
  • The stock has a 52-week high of $189.78, which may indicate that it is nearing its peak, leading to potential volatility and risk for new investors.
  • Insider selling activity has been noted, with significant shares sold by executives, which could signal a lack of confidence in the company's short-term prospects.
  • The company operates in a highly competitive healthcare market, which may pose risks to its market share and profitability in the long run.

JNJ Forecast - Frequently Asked Questions

According to the research reports of 22 Wall Street equities research analysts, the average twelve-month stock price forecast for Johnson & Johnson is $191.41, with a high forecast of $215.00 and a low forecast of $153.00.

22 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Johnson & Johnson in the last twelve months. There are currently 8 hold ratings, 12 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" JNJ shares.

According to analysts, Johnson & Johnson's stock has a predicted upside of 0.23% based on their 12-month stock forecasts.

Over the previous 90 days, Johnson & Johnson's stock had 4 upgrades by analysts.

Analysts like Johnson & Johnson more than other "medical" companies. The consensus rating for Johnson & Johnson is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how JNJ compares to other companies.


This page (NYSE:JNJ) was last updated on 10/9/2025 by MarketBeat.com Staff
From Our Partners